Pubmed - Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study

The Psychiatric Unit, University Medical School, Wroclaw, Poland.

Abstract

A proline-rich polypeptide (PRP) complex, subsequently called Colostrinin, was isolated from colostrum. The complex showed immunomodulatory properties in mice, rats, and chickens, inducing maturation and differentiation of thymocytes. 

It was recently found that Colostrinin is a cytokine-like factor that acts as an inducer of interferon gamma (IFN-gamma) and other cytokines in human peripheral blood and cord blood leukocyte cultures and has psycho-immuno-enhancing activity in volunteers. These observations prompted us to study the effect of Colostrinin on patients with Alzheimer's disease (AD). Forty six AD patients were divided into 3 groups and randomly assigned to receive orally either Colostrinin (100 microg per tablet, every second day), commercially available bioorganic selenium (100 microg selenium per tablet, every second day) or placebo tablets. One cycle of the treatment lasted 3 weeks and was separated from the next cycle by a 2 week hiatus. Each patient received 10 cycles of treatment during the year of the clinical trial. 

Outcomes were assessed by psychiatrists blinded to the treatment assignment. Eight of the 15 AD patients treated with Colostrinin improved and in the 7 others the disease had stabilized. In contrast, none of the 31 patients from the selenium or placebo groups with similar mild or moderate AD improved. The administration of selenium promoted stabilization in 13 of the 15 patients, whereas in the placebo group only 8 of the 16 patients were stabilized at the 12 month trials end-evaluation. 

Colostrinin was found to be a remarkably safe drug. Mild and transient effects were anxiety, stimulation, insomnia, and tiredness. The results obtained showed that oral administration of Colostrinin improves the outcome of AD patients with mild to moderate dementia. The results are very encouraging and deserve further research.

http://www.ncbi.nlm.nih.gov/pubmed/10608295

Pubmed - Effect of bovine colostrum on anaerobic exercise performance and plasma insulin-like growth factor

School of Health Sciences, University of South Australia, Holbrooks Road, Underdale, SA 5032, Australia. j.buckley@unisa.edu.au

Abstract

In this study, we examined the effects of bovine colostrum on peak vertical jump power (VJpeak), peak cycle power (CPpeak), alactic anaerobic work capacity, resistance exercise one-repetition maxima (1-RM) and plasma insulin-like growth factor I (IGF-I) concentrations. 

Using a randomized, double-blind, placebo-controlled, parallel design, 51 males completed 8 weeks of resistance and plyometric training while consuming 60 g x day(-1) of bovine colostrum (n = 26) or concentrated whey protein powder (n = 25). Peak vertical jump power, peak cycle power, alactic anaerobic work capacity, 1-RM and plasma IGF-I were not different between groups at baseline (P > 0.33). 

Peak vertical jump power and peak cycle power were still not significantly different between groups by week 4 (VJpeak: bovine colostrum, 7231 +/- 488 W; whey protein, 7214 +/- 530 W; P = 0.99; CPpeak: bovine colostrum, 1272 +/- 202 W; whey protein, 1232 +/- 208 W; P = 0.99). 

By week 8, however, peak vertical jump power (bovine colostrum, 7370 +/- 503 W; whey powder, 7237 +/- 481 W; 95% confidence intervals, 54 to 170 W; P < 0.01) and peak cycle power (bovine colostrum, 1400 +/- 215 W; whey protein, 1311 +/- 192 W; 95% confidence intervals, 20 to 61 W; P < 0.01) were significantly higher in the bovine colostrum condition. Alactic anaerobic work capacity and 1-RM increased (P < 0.001), but the increases were not different between groups (P > 0.08). Plasma IGF-I did not change in either group (P = 0.55). 

We conclude that bovine colostrum supplementation during training significantly increased peak anaerobic power, but had no effect on alactic anaerobic work capacity, 1-RM or plasma IGF-I.

http://www.ncbi.nlm.nih.gov/pubmed/12848392

Pubmed - Analysis of bovine immunoglobulin G in milk, colostrum and dietary supplements: a review

Fonterra Research Centre, Dairy Farm Road, Private Bag 11029, Palmerston North, New Zealand.

Abstract

The immunoprotective properties of bovine milk immunoglobulin G (IgG) have led to a recent proliferation of nutritional products incorporating this protein. It has therefore become critical that reliable analytical techniques for the measurement of the IgG content in such products are available. This literature review surveys current methods of analysis for IgG, including separation-based or immuno-based concentration analysis. The review also discusses nutraceutical applications, regulatory issues, stability of IgG and the significance of primary reference material in IgG analysis.

http://www.ncbi.nlm.nih.gov/pubmed/17579844

Pubmed - Bovine colostrum is a health food supplement which prevents NSAID induced gut damage

University Division of Gastroenterology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK.

Abstract

BACKGROUND:

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective for arthritis but cause gastrointestinal injury. Bovine colostrum is a rich source of growth factors and is marketed as a health food supplement.

AIMS:

To examine whether spray dried, defatted colostrum or milk preparations could reduce gastrointestinal injury caused by indomethacin.

METHODS:

Effects of test solutions, administered orally, were examined using an indomethacin restraint rat model of gastric damage and an indomethacin mouse model of small intestinal injury. Effects on migration of the human colonic carcinoma cell line HT-29 and rat small intestinal cell line RIE-1 were assessed using a wounded monolayer assay system (used as an in vitro model of wound repair) and effects on proliferation determined using [3H]thymidine incorporation.

RESULTS:

Pretreatment with 0.5 or 1 ml colostral preparation reduced gastric injury by 30% and 60% respectively in rats. A milk preparation was much less efficacious. Recombinant transforming growth factor beta added at a dose similar to that found in the colostrum preparation (12.5 ng/rat), reduced injury by about 60%. Addition of colostrum to drinking water (10% vol/vol) prevented villus shortening in the mouse model of small intestinal injury. Addition of milk preparation was ineffective.Colostrum increased proliferation and cell migration of RIE-1 and HT-29 cells. These effects were mainly due to constituents of the colostrum with molecular weights greater than 30 kDa.

CONCLUSIONS:

Bovine colostrum could provide a novel, inexpensive approach for the prevention and treatment of the injurious effects of NSAIDs on the gut and may also be of value for the treatment of other ulcerative conditions of the bowel.

http://www.ncbi.nlm.nih.gov/pubmed/10205201

Pubmed - Effect of bovine colostrum supplementation on respiratory tract mucosal defenses in swimmers

Dept. of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.

Abstract

PURPOSE:

This study investigated the effect of bovine colostrum (BC) on mucosal defense in the respiratory tracts of athletes and a nonexercising control group.

METHODS:

An athlete cohort (ATH) of 25 (12 male, 13 female) elite swimmers (age 14-23 yr) and a control cohort (CON) of 28 (9M, 19F) students (age 18-27 yr) were randomly allocated in a double-blind manner to receive either 25 g BC (low-proteincolostrum powder) or isocaloric placebo (PL) per day for 10 wk. Postprandial saliva samples were analyzed for immunoglobulins (A, G, and M) and osmolality at baseline, after 4 and 10 wk, and 2 wk postsupplementation. Blood samples were analyzed for immunoglobulins and C-reactive protein at baseline, after 5 and 10 wk, and 2 wk postsupplementation. Dietary intake was assessed by self-recorded dietary records. Upper respiratory tract symptoms (URS) and exercise were also self-recorded daily.

RESULTS:

There was no significant time-related effect of the BC supplement on either saliva or plasma immunoglobulin levels for either cohort. After 4 wk supplementation fewer ATH/BC (25%) than ATH/PL participants (61%) reported URS incidents (p = .062). No significant difference occurred in URS reports in the control group.

CONCLUSION:

There was no measurable effect on immunoglobulin levels of consuming BC, which is in contrast to effects that have been reported previously in marathon runners, indicating that the effect of BC supplementation is not universal in all groups of athletes. Fewer athletes reported URS (although cause unknown) when consuming BC, which may be advantageous for training.

http://www.ncbi.nlm.nih.gov/pubmed/20601740

Pubmed - Neuroprotective effects of consuming bovine colostrum after focal brain ischemia/reperfusion injury in rat model

Department of Emergency Medicine, College of Medicine, Kyung Hee University, Seoul 130-702, Korea.

Abstract

To investigate the neuroprotective effects of bovine colostrums (BC), we evaluate the ability of consuming BC after focal brain ischemia/reperfusion injury rat model to reduce serum cytokine levels and infarct volume, and improve neurological outcome. Sprague-Dawley rats were randomly divided into 4 groups; one sham operation and three experimental groups. In the experimental groups, MCA occlusion (2 h) and subsequent reperfusion (O/R) were induced with regional cerebral blood flow monitoring. One hour after MCAO/R and once daily during the experiment, the experimental group received BC while the other groups received 0.9% saline or low fat milk (LFM) orally. Seven days later, serum pro-inflammatory cytokine (IL-1beta, IL-6, and TNF-alpha) and anti-inflammatory cytokine (IL-10) levels were assessed. Also, the infarct volume was assessed by using a computerized image analysis system. Behavioral function was also assessed using a modified neurologic severity score and corner turn test during the experiment. Rats receiving BC after focal brain I/R showed a significant reduction (-26%/-22%) in infarct volume compared to LFM/saline rats, respectively (P < 0.05). Serum IL-1beta, IL-6, and TNF-alpha levels were decreased significantly in rats receiving BC compared to LFM/saline rats (P < 0.05). In behavioral tests, daily BC intake showed consistent and significant improvement of neurological deficits for 7 days after MCAO/R. BC ingestion after focal brain ischemia/reperfusion injury may prevent brain injury by reducing serum pro-inflammatory cytokine levels and brain infarct volume in a rat model.

http://www.ncbi.nlm.nih.gov/pubmed/20607064

Pubmed - Diarrhea: the nemesis of the artificially reared, early weaned piglet and a strategy for defense

Abstract

Rearing early weaned piglets artificially for the purpose of increasing the efficiency of the sow is an attractive management concept. However, high death losses resulting from diarrhea in artificially reared piglets have dampered enthusiasm for early weaning. Enterotoxigenic Escherichia coli, transmissible gastroenteritis virus and rotavirus are the three main enteropathogens responsible for causing the diarrhea. The enteropathogens infect the small intestine, which produces a secretory or malabsorptive diarrhea. In nature, the nursing piglet is protected from the enteropathogens by antibody bathing his gut. The source of the antibody is the dam's colostrum and milk. It should be possible to protect artificially reared, early weaned piglets from enteropathogens by feeding them diets that contain antibodies to putative enteropathogens.

PMID:

 

3021707

 

http://www.ncbi.nlm.nih.gov/pubmed/3021707